Article

Spatial, Temporal, and Molecular Heterogeneity of ADC targets in High-Grade Serous Ovarian Carcinoma

2025-12-05

Abstract excerpt

<h4>Background</h4> Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for high-grade serous ovarian carcinoma (HGSOC). Patient selection for ADC therapy depends on tumor target expression, making it essential to characterize molecular, spatial, and temporal heterogeneity. <h4>Methods</h4> We analyzed two HGSOC tissue microarray cohorts: 100 genomically profiled primaries (1,565 cores) an...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 431ff0f6-a849-5379-a913-19d72d1104b6
DOI: 10.64898/2025.12.05.25341695

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Spatial, Temporal, and Molecular Heterogeneity of ADC targets in High-Grade Serous Ovarian CarcinomaDOI 10.64898/2025.12.05.25341695Read

Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma.Semantic proximity Read

Multi-Omic Profiling Reveals Antibody-Drug Conjugate Targetability in Ovarian CancerSemantic proximity Read

The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancerSemantic proximity Read

Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors of The Cancer Genome Atlas: exploration beyond single-agent therapySemantic proximity Read

RB1 expression and HR proficiency define a poor-outcome molecular subtype of high grade serous ovarian carcinomaSemantic proximity Read

Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.Semantic proximity Read

Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processesSemantic proximity Read

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaSemantic proximity Read

Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinomaSemantic proximity Read

Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian CancerSemantic proximity Read

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatmentSemantic proximity Read

Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer.Semantic proximity Read